Recombinant erythropoietin (rHuEPO) has heralded a transformative era in anaemia management, particularly among chronic renal failure patients, engendering increased survival rates, reduced hospitalizations, enhanced cognitive function, and elevated quality of life [44]. The gene discussed is EPO; the disease is chronic kidney disease.